John Skidmore

Chief Scientific Officer

University of Cambridge

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

John Skidmore is the Chief Scientific Officer at the University of Cambridge, UK. His research focuses on the development of selective inhibitors for various molecular targets, particularly in the context of neurodegenerative diseases and cancer. Recent publications include studies on NUAK1 inhibitors and the impact of Ca2+ channel modulation in Alzheimer’s disease. He also investigates the permeability of PROTACs and their efficacy in targeting specific protein interactions.

Articles (9)

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2020

Collaborators (2)

Timothy Sharpe

Head of Facility

Universität Basel Department Biozentrum

SWITZERLAND

View details

David Attwell

University College London

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

John Skidmore

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

Development of Purine and Pyrrolopyrimidine Scaffolds as Potent, Selective, and Brain Penetrant NUAK1 Inhibitors

Development of the Pyrido[2,3-d]pyrimidin-7(8H)-one Scaffold toward Potent and Selective NUAK1 Inhibitors

Inhibiting Ca2+ channels in Alzheimer’s disease model mice relaxes pericytes, improves cerebral blood flow and reduces immune cell stalling and hypoxia

The Identification of Potent, Selective, and Brain Penetrant PI5P4Kγ Inhibitors as In Vivo-Ready Tool Molecules

Identification of ARUK2002821 as an isoform-selective PI5P4Kα inhibitor

The rational design of ARUK2007145, a dual inhibitor of the α and γ isoforms of the lipid kinase phosphatidylinositol 5-phosphate 4-kinase (PI5P4K)

The different autophagy degradation pathways and neurodegeneration

A small-molecule inhibitor of the BRCA2-RAD51 interaction modulates RAD51 assembly and potentiates DNA damage-induced cell death.

Systematic Investigation of the Permeability of Androgen Receptor PROTACs

Collaborators (2)

Timothy Sharpe

David Attwell

Make your next move.